Dr Marilyn Huang considers the use of biomarkers in the diagnosis, prognosis and treatment for cervical cancer. She presents an overview of how biomarkers are used in clinical practice, the data supporting their use and her view on the most promising emerging biomarkers.1/3 Next Interview
Dr Julius Strauss describes the key features of the tumour microenvironment, the oncogenic activity of human papillomavirus (HPV) and the mechanisms of immune escape, highlighting how different molecular targets can be exploited for therapeutic purposes.2/3 Next Interview
Prof. Isabelle Ray-Coquard outlines the current standard of care for patients with advanced, metastatic and recurrent cervical cancer. She presents the latest data on emerging immunotherapy options and antibody-drug conjugates.3/3 Take CME Test
Overview & Learning Objectives
In this activity, experts in cervical cancer consider the place for biomarkers, the role of the tumour microenvironment in disease development and progression, and emerging treatment options for advanced or metastatic cervical cancer.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of gynaecological oncologists, oncologists and oncology nurses.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Dr Marilyn Huang discloses: Grant support from Merck.
Dr Julius Strauss discloses: Grant/research support to the National Institutes of Health (NIH) from EMD Serono Inc, Precigen and PDS Biotechnology for research on human papillomavirus (HPV)-associated malignancies. Dr Strauss is listed on a National Institutes of Health patent for the combined use of programmed death-ligand 1 (PD-L1) and transforming growth factor (TGF) beta blockade in HPV-associated malignancies.
Prof. Isabelle Ray-Coquard discloses: Consultant/Advisory Boards for AstraZeneca, Clovis Oncology, MSD, Bristol Myers Squibb and GlaxoSmithKline.
Walter Murray Yarbrough, MD, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AME). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Date of original release: 10 December 2020. Date credits expire: 10 December 2021.
After watching this activity, you should be able to:
- Recognize the importance of biomarker testing in the screening and monitoring of cervical cancer
- Discuss the role of the tumour microenvironment in the development and progression of invasive cervical cancer
- Interpret the most recent data for new potential therapies for advanced or recurrent cervical cancer